Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs

Madela, Karolina and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2012. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Medicinal Chemistry 4 (5) , pp. 625-650. 10.4155/fmc.12.10

Full text not available from this repository.

Abstract

The search for new anti-hepatitis C virus (HCV) therapeutics continues as the current treatment, consisting of PEGylated IFN-a and ribavirin, is of limited efficacy, nonspecific and can cause significant side effects. Modified nucleoside analogues with improved efficacy and selectivity, may become the backbone of the future standard of care for anti-HCV therapies. Several families of modified nucleoside are known to inhibit HCV RNA-dependent RNA polymerase, a vital enzyme for viral replication. Ongoing efforts are focused on improvement of potency, selectivity and delivery of antiviral nucleoside analogues, with several recent promising advances into clinical trials. This review summarizes the current progress in the development of new anti-HCV nucleoside and nucleotide prodrugs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Future Science Ltd
ISSN:	1756-8919
Last Modified:	19 Oct 2022 09:58
URI:	https://orca.cardiff.ac.uk/id/eprint/22821

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item